Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity in vivo

Lesley M. Voss, Chella S. David, Stephen D. Showalter, Carlos V. Paya, Paul J. Leibson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Heteroconjugate antibodies are generated by covalently linking two mAbs with different specificities. When antl-CD3 mAb, capable of activating effector T cells, is coupled to anti-herpes simplex virus (HSV) mAb, which binds HSV antigens on virally-lnfected target cells, the resulting heteroconjugate antibody can be used In vitro to enhance anti-HSV immunity. Specifically, these heteroconjugate antibodies can augment antl-HSV immunity among lymphocytes previously lacking cytotoxicity against HSV-infected target cells. However, the efficacy of these specialized reagents in enhancing anti-HSV Immunity in vivo has not been determined. We report here that anti-HSV heteroconjugates used In an adoptive transfer murine model of HSV-1 infection inhibited HSV replication in vivo and Improved long-term survival. These results demonstrate that heteroconjugate antibodies have a potential therapeutic role in enhancement of anti-HSV immunity.

Original languageEnglish (US)
Pages (from-to)417-420
Number of pages4
JournalInternational Immunology
Issue number3
StatePublished - Mar 1992


  • Adoptive transfer
  • Anti-CD3 mAb
  • Immunotherapy
  • Viral antigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity in vivo'. Together they form a unique fingerprint.

Cite this